SRT-2104

SRT-2104 is an experimental drug that was studied by Sirtris Pharmaceuticals as a small-molecule activator of the sirtuin subtype SIRT1. The compound progressed to Phase II human trials for Type II diabetes before development was discontinued, however it continues to be widely used in animal research into the functions of SIRT1.^{[1][2][3][4][5]}

SRT-2104

Identifiers
IUPAC name 4-methyl-N-[2-[3-(morpholin-4-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]-2-pyridin-3-yl-1,3-thiazole-5-carboxamide
CAS Number	1093403-33-8
PubChem CID	25108829
DrugBank	DB12186 Y
ChemSpider	28637794
UNII	4521NR0J09
ChEMBL	ChEMBL4297436
CompTox Dashboard (EPA)	DTXSID00648729
Chemical and physical data
Formula	C26H24N6O2S2
Molar mass	516.64 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(SC(=N1)C2=CN=CC=C2)C(=O)NC3=CC=CC=C3C4=CN5C(=CSC5=N4)CN6CCOCC6
InChI InChI=1S/C26H24N6O2S2/c1-17-23(36-25(28-17)18-5-4-8-27-13-18)24(33)29-21-7-3-2-6-20(21)22-15-32-19(16-35-26(32)30-22)14-31-9-11-34-12-10-31/h2-8,13,15-16H,9-12,14H2,1H3,(H,29,33) Key:LAMQVIQMVKWXOC-UHFFFAOYSA-N

See also

• SRT-1460
• SRT-1720
• SRT-2183
• SRT-3025
• STAC-9